Home
PHVS
PHVS News

Latest Pharvaris N.V. (PHVS) News on June 3, 2025

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

GlobeNewswire

13 hours ago

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

GlobeNewswire

15 days ago

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

MT Newswires

19 days ago

Wedbush Adjusts Pharvaris Price Target to $17 From $25, Maintains Outperform Rating

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

20 days ago

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

GlobeNewswire

22 days ago

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

MT Newswires

a month ago

Cantor Fitzgerald Initiates Pharvaris at Overweight With $28 Price Target

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

2 months ago

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

MT Newswires

2 months ago

Pharvaris Says EU Orphan Designation Received for Deucrictibant

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

GlobeNewswire

2 months ago

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

GlobeNewswire

3 months ago

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

GlobeNewswire

3 months ago

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Simply Wall St.

3 months ago

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Why Pharvaris (PHVS) Is Advancing Today

Insider Monkey

4 months ago

Why Pharvaris (PHVS) Is Advancing Today

Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now?

Insider Monkey

4 months ago

Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now?

Pharvaris Outlines 2025 Strategic Priorities

GlobeNewswire

5 months ago

Pharvaris Outlines 2025 Strategic Priorities

Pharvaris price target lowered to $46 from $50 at JMP Securities

TipRanks

6 months ago

Pharvaris price target lowered to $46 from $50 at JMP Securities

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

GlobeNewswire

7 months ago

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

GlobeNewswire

7 months ago

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

GlobeNewswire

7 months ago

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

GlobeNewswire

8 months ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris to Host Virtual Investor Event on October 23, 2024

GlobeNewswire

8 months ago

Pharvaris to Host Virtual Investor Event on October 23, 2024

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

GlobeNewswire

8 months ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

MT Newswires

8 months ago

JonesTrading Initiates Coverage on Pharvaris With Buy Rating, $46 Price Target

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

8 months ago

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

GlobeNewswire

9 months ago

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

GlobeNewswire

9 months ago

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Pharvaris Presents Data at the Bradykinin Symposium 2024

GlobeNewswire

9 months ago

Pharvaris Presents Data at the Bradykinin Symposium 2024

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

GlobeNewswire

9 months ago

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

10 months ago

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Three Surprising Names That Could Be On Biogen's Buyout Shortlist

Investor's Business Daily

a year ago

Three Surprising Names That Could Be On Biogen's Buyout Shortlist

Pharvaris Announces Annual Meeting of Shareholders

GlobeNewswire

a year ago

Pharvaris Announces Annual Meeting of Shareholders

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

GOBankingRates

a year ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

a year ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

a year ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

a year ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Insider Monkey

a year ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow

AFP

a year ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

Investor's Business Daily

a year ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

The Wall Street Journal

a year ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

GlobeNewswire

a year ago

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

GlobeNewswire

a year ago

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

a year ago

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

GlobeNewswire

a year ago

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

GlobeNewswire

a year ago

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

GlobeNewswire

a year ago

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

GlobeNewswire

a year ago

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

GlobeNewswire

a year ago

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

GlobeNewswire

a year ago

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Pharvaris Announces Extraordinary Meeting of Shareholders

GlobeNewswire

a year ago

Pharvaris Announces Extraordinary Meeting of Shareholders

Business Wire

a year ago

Early Repurchase(s)

Yacktman Asset Management Adjusts Portfolio, Weatherford International PLC Sees Significant ...

GuruFocus.com

a year ago

Yacktman Asset Management Adjusts Portfolio, Weatherford International PLC Sees Significant ...

GardaWorld Amends Maturity Date of its Term Loan B due 2026 to 2029 and Enters Into an Incremental Term Loan of US$200 Million

CNW Group

a year ago

GardaWorld Amends Maturity Date of its Term Loan B due 2026 to 2029 and Enters Into an Incremental Term Loan of US$200 Million

‘World’s Most Romantic Building:’ Empire State Building Celebrates Valentine’s Day with NYC's Most Romantic Date Experience, Engagement Package, and Film Screenings

Business Wire

a year ago

‘World’s Most Romantic Building:’ Empire State Building Celebrates Valentine’s Day with NYC's Most Romantic Date Experience, Engagement Package, and Film Screenings

ePlus Acquires PEAK Resources, Inc.

PR Newswire

a year ago

ePlus Acquires PEAK Resources, Inc.

Phenomenex Launches PhenoAcademy for Cutting-Edge Chromatography Education

PR Newswire

a year ago

Phenomenex Launches PhenoAcademy for Cutting-Edge Chromatography Education

ATEC to Present at Upcoming Conferences

Business Wire

a year ago

ATEC to Present at Upcoming Conferences

Pharvaris to Present at the WSAAI Annual Meeting 2024

GlobeNewswire

a year ago

Pharvaris to Present at the WSAAI Annual Meeting 2024

Wiley Hosts Investor Update

Business Wire

a year ago

Wiley Hosts Investor Update

Amphenol's (APH) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Zacks

a year ago

Amphenol's (APH) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

a year ago

Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program

Zacks

a year ago

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program

Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision

Investor's Business Daily

a year ago

Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

GlobeNewswire

a year ago

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Apollo Commercial Real Estate Finance, Inc. Announces Dates for Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

GlobeNewswire

a year ago

Apollo Commercial Real Estate Finance, Inc. Announces Dates for Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

3 Picks from the Attractive Internet Services Industry

Zacks

a year ago

3 Picks from the Attractive Internet Services Industry

CoreCivic (NYSE:CXW) May Have Issues Allocating Its Capital

Simply Wall St.

a year ago

CoreCivic (NYSE:CXW) May Have Issues Allocating Its Capital

3 Precious Metals Stocks That Will Shine in 2024

InvestorPlace

a year ago

3 Precious Metals Stocks That Will Shine in 2024

16 Best Mid-Cap Growth Stocks To Buy Now

Insider Monkey

a year ago

16 Best Mid-Cap Growth Stocks To Buy Now

SEMrush Holdings Inc President Eugenie Levin Sells 44,223 Shares

GuruFocus.com

a year ago

SEMrush Holdings Inc President Eugenie Levin Sells 44,223 Shares

Growth Stocks on the Brink: 7 Picks Poised for Explosive Returns

InvestorPlace

a year ago

Growth Stocks on the Brink: 7 Picks Poised for Explosive Returns

MarketAxess to Host Conference Call Announcing Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, January 31, 2024

Business Wire

a year ago

MarketAxess to Host Conference Call Announcing Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, January 31, 2024

Reuters

a year ago

PRESS DIGEST- Financial Times - Jan. 10

Calculating The Intrinsic Value Of John Wiley & Sons, Inc. (NYSE:WLY)

Simply Wall St.

a year ago

Calculating The Intrinsic Value Of John Wiley & Sons, Inc. (NYSE:WLY)

American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2023 Earnings Release Date and Conference Call Information

GlobeNewswire

a year ago

American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2023 Earnings Release Date and Conference Call Information

MGIC Investment (MTG) Rises 50% in a Year: More Upside Left?

Zacks

a year ago

MGIC Investment (MTG) Rises 50% in a Year: More Upside Left?

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

GlobeNewswire

a year ago

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

Wyoming State Parks' New Reservation Site is Now Live, Powered by Tyler Technologies

Business Wire

a year ago

Wyoming State Parks' New Reservation Site is Now Live, Powered by Tyler Technologies

Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy?

Zacks

a year ago

Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy?

How Clear Secure Is Building Its Business

Motley Fool

a year ago

How Clear Secure Is Building Its Business

Are Investors Undervaluing ArcBest (ARCB) Right Now?

Zacks

a year ago

Are Investors Undervaluing ArcBest (ARCB) Right Now?

Mosaic's (NYSE:MOS) Dividend Will Be Increased To $0.21

Simply Wall St.

a year ago

Mosaic's (NYSE:MOS) Dividend Will Be Increased To $0.21

15 Quality Undervalued Non-Cyclical Stocks to Buy Now

Insider Monkey

a year ago

15 Quality Undervalued Non-Cyclical Stocks to Buy Now

Artificial Intelligence in Healthcare: 3 Stocks Transforming the Industry

InvestorPlace

a year ago

Artificial Intelligence in Healthcare: 3 Stocks Transforming the Industry

Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms who were rewarded as market cap surged US$578m last week

Simply Wall St.

a year ago

Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms who were rewarded as market cap surged US$578m last week

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

GlobeNewswire

a year ago

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal

Zacks

a year ago

Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal

Quontic Bank Launches Alkami's Digital Banking Solution

PR Newswire

a year ago

Quontic Bank Launches Alkami's Digital Banking Solution

When Will Sabre Corporation (NASDAQ:SABR) Breakeven?

Simply Wall St.

2 years ago

When Will Sabre Corporation (NASDAQ:SABR) Breakeven?

Share on Social Networks: